Stemmer, Salomon M.
Steiner, Mariana
Rizel, Shulamith
Ben-Baruch, Noa
Uziely, Beatrice
Jakubowski, Debbie M.
Baron, Julie
Shak, Steven
Soussan-Gutman, Lior
Bareket-Samish, Avital
Fried, Georgeta
Rosengarten, Ora
Itay, Amit
Nisenbaum, Bella
Katz, Daniela
Leviov, Michelle
Tokar, Margarita
Liebermann, Nicky
Geffen, David B.
Funding for this research was provided by:
Teva Pharmaceutical Industries (1132, 1132, 1132, 1132, 1132, 1132, 1132, 1132, 1132, 1132, 1132, 1132, 1132, 1132, 1132)
Article History
Received: 25 May 2019
Accepted: 25 September 2019
First Online: 8 November 2019
Competing interests
: S.M.S. reports receiving grant funding from Teva; receiving travel expenses from Genomic Health, Inc.; conducting research funded by Teva. N.B. reports receiving honoraria from Teva, and serving on the speaker’s bureau of Genomic Health. D.M.J., J.B., and S.S. report being employed by Genomic Health. D.M.J., J.B., and S.S. report having stock ownership in Genomic Health. S.S. reports having intellectual property interest in Genomic Health and a leadership role at Genomic Health. L.S.G. reports being employed by and holding stock options in Teva Pharmaceutical Industries Ltd. A.B.S. reports being a consultant/medical writer for Teva Pharmaceutical Industries Ltd., Genomic Health Inc. (including for the purpose of the current study), Bayer, and Roche. M.S., S.R., B.U., G.F., O.R., A.I., B.N., D.K., M.L., M.T., N.L., and D.B.G. declare no competing interests.